Ansa Biotechnologies, Inc.
Contrasting his experience with what he knew about computer science, Lin-Arlow remembers thinking that “If it took a month to recompile code, we wouldn't have all this tech that we now enjoy and that’s changed the world — but that’s what it feels like in many cases when you’re engineering cells.
Now, just five years after reporting that first 10-mer, Ansa has nearly met their goal of routinely providing 1000-mers to the market.In an important next step toward reaching that goal, Ansa launched theirlast month, which provides synthetic DNA constructs to a select group of partners.
Eventually, he says, Ansa will offer pooled oligos, asking me to imagine an array synthesizer that can make hundreds of thousands or even millions of very large gene-length oligos. It might seem like a pipe dream, but people are asking for it, says Lin-Arlow — and he plans to deliver.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Revolut CFO to depart company after two years, company saysInsider tells the global tech, finance, markets, media, healthcare, and strategy stories you want to know.
Fonte: BusinessInsider - 🏆 729. / 51 Consulte Mais informação »